ApoA-I technology is recognized for its ability to transform the
treatment of cardiovascular disease
TSX Exchange Symbol: RVX
CALGARY, Nov. 29 /CNW/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is
pleased to announce today that the World Economic Forum has selected
Resverlogix as a winner of the very prestigious Technology Pioneer Award in
recognition of its NexVas(TM) Plaque Removal program. Candidates for this
award must be involved in the development of life-changing technologies and
have potential for long-term impact on business and society.
"We are elated to receive this high-level recognition from such an
important leading global body as the World Economic Forum. This awareness that
our innovative technology could have such a dramatic positive impact for
society, as it relates to the future treatment of cardiovascular disease
(CVD), further validates the positive direction of our NexVas technology,"
stated Mr. Donald McCaffrey, President, CEO & Co-Founder of Resverlogix.
Resverlogix was selected because it is developing exceptionally promising
new molecules that increase the production of ApoA-l and high density
lipoprotein (HDL) for the treatment of atherosclerosis. According to the World
Health Organization, CVD is the number one cause of death globally, an immense
problem currently responsible for killing nearly 18 million people annually
"I would like to offer Canada's sincere congratulations to Resverlogix
for winning this international award from the World Economic Forum," said the
Honourable Minister Jim Prentice, Minister of Industry. "Resverlogix is doing
some incredible work in advancing the treatment of atherosclerosis, the major
underlying cause of cardiovascular disease and this award is a testament to
Canada's world-class biopharmaceutical industry."
Dr. Norman Wong, M.D., Co-Founder of Resverlogix added, "Current
therapies have made significant strides in improving outcomes but are only
able to address 30 percent of the risk associated with CVD. Consequently there
exists a significant unmet medical need for a therapy to address the remaining
70 percent of risk. The proven ability of our drug to increase the production
of ApoA-I and functional HDL, offers enormous potential to address this
critical unmet need and impact the leading killer in the world".
The Technology Pioneers 2008 were nominated by the world's leading
venture capital and technology companies. The final selection from
273 nominees was made by a panel of leading technology experts appointed by
the World Economic Forum. To be selected as a Technology Pioneer, a company
must be involved in the development of life-changing technology innovation and
have potential for long-term impact on business and society. In addition, it
must demonstrate visionary leadership, show the signs of being a long-standing
market leader - and its technology must be proven. The award winners are
companies that have been identified as developing and applying highly
transformational and innovative technologies in the areas of energy,
biotechnology and health, and information technology. Previous Technology
Pioneers have included Business Objects, Gilead Sciences, Corel Corporation,
Encore Software, Google, Mozilla Corporation and Napster.
Only one of the Technology Pioneers 2008 is based in Canada while
23 companies are US-based. Israel and Switzerland each boast three; the United
Kingdom and Sweden two each; and France, Germany, India, the Netherlands and
Russia, one each. Technology Pioneers are nominated in three main categories:
Biotechnology/Health Energy/Environment, and Information Technology.
"This year the World Economic Forum received a record number of
applications from companies around the world to become a Technology Pioneer.
From a highly competitive field, we are extremely pleased to have a community
that is using innovation and technology to dramatically affect the way society
and business operate and doing so in a markedly collaborative manner. We are
excited to welcome the Technology Pioneers class of 2008 to the larger
community of the World Economic Forum and we are looking forward to the fruits
that their collaboration will bring," said Peter Torreele, Managing Director
of the World Economic Forum.
The entire list of Technology Pioneers and interviews with the CEOs of
the selected companies can be found here:
About Cardiovascular Disease (CVD)
CVD can be generally defined as any abnormal condition characterized by
dysfunction of the heart and blood vessels. CVD includes atherosclerosis
(especially coronary heart disease which can lead to heart attacks),
cerebrovascular disease (stroke), and hypertension (high blood pressure). The
underlying cause of most CVD is a gradual clogging of the arteries
(atherosclerosis) that supply blood to the heart, brain and other vital
The American Heart Association estimates that almost 80 million American
Adults have one or more types of cardiovascular disease. CVD remains the
number one killer of developed nations. Nearly 2,400 Americans die each day
from cardiovascular disease - that is 1 person will die every 36 seconds.
Apolipoprotein A-I (ApoA-I), the main component of high-density
lipoprotein (HDL) represent the body's natural defense system against
atherosclerosis by mediating reverse cholesterol transport, i.e. transport of
peripheral cholesterol including that of the vessel wall to the liver for
processing. In multiple human and animal studies over-expression or repeated
infusion of ApoA-I inhibit progression and induce regression of
atherosclerosis in animals and humans.
About the World Economic Forum
The World Economic Forum is an independent international organization
committed to improving the state of the world by engaging leaders in
partnerships to shape global, regional and industry agendas.
Incorporated as a foundation in 1971, and based in Geneva, Switzerland,
the World Economic Forum is impartial and not-for-profit; it is tied to no
political, partisan or national interests. (www.weforum.org)
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet needs. The NexVas(TM) program is the Company's primary focus
which is to develop novel small molecules that enhance ApoA-I. These vital
therapies address the grievous burden of atherosclerosis and other important
diseases such as acute coronary syndrome, diabetes, Alzheimer's and other
vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a
program that aims to address burgeoning grievous diseases, such as cancer and
fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX).
For further information please visit www.resverlogix.com.
This news release may contain certain forward-looking statements that
reflect the current views and/or expectations of Resverlogix Corp. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly. The TSX Exchange does not accept
responsibility for the adequacy or accuracy of this news release.
Notes to Editors:
- Go to http://www.weforum.org/techpioneers/2008 for the entire list of
Technology Pioneers and interviews with the CEOs of the selected
- Download print-quality high resolution photographs of the CEOs of the
selected companies at: http://www.pbase.com/forumweb/techpioneers2008
For further information:
For further information: Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp., Phone: (403) 473-5359, Fax: (403) 256-8495, Email:
Theresa@resverlogix.com; Sarah Zapotichny, Manager, Investor Relations,
Resverlogix Corp., Phone: (403) 254-9252, Fax: (403) 256-8495, Email:
Sarah@resverlogix.com; Website: www.resverlogix.com